Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Income towards Parent Company: 2018-2024

Historic Income towards Parent Company for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to -$12.0 million.

  • Pharming Group N.V's Income towards Parent Company rose 1255.41% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 495.63%. This contributed to the annual value of -$12.0 million for FY2024, which is 283.16% down from last year.
  • According to the latest figures from FY2024, Pharming Group N.V's Income towards Parent Company is -$12.0 million, which was down 283.16% from -$3.1 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Income towards Parent Company ranged from a high of $37.7 million in FY2020 and a low of -$12.0 million during FY2024.
  • For the 3-year period, Pharming Group N.V's Income towards Parent Company averaged around $2.5 million, with its median value being -$3.1 million (2023).
  • Per our database at Business Quant, Pharming Group N.V's Income towards Parent Company skyrocketed by 418.42% in 2022 and then plummeted by 283.16% in 2024.
  • Yearly analysis of 5 years shows Pharming Group N.V's Income towards Parent Company stood at $37.7 million in 2020, then plummeted by 118.70% to -$7.1 million in 2021, then skyrocketed by 418.42% to $22.5 million in 2022, then plummeted by 113.90% to -$3.1 million in 2023, then plummeted by 283.16% to -$12.0 million in 2024.